← All trials
NCT05922813
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Mar 10, 2023
- Completion date
- Apr 12, 2023
- First posted
- Jun 28, 2023
- Last posted
- Jun 28, 2023
- Enrollment
- 257
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BMI KoreaLead sponsor
- Chung-Ang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.